BRISTOL MYERS SQUIBB

Bristol Myers Squibb to Demonstrate the Strength of its Growing Cardiovascular Portfolio at the American College of Cardiology’s 71st Annual Scientific Session

Retrieved on: 
Monday, March 21, 2022
Health, Clinical Trials, Research, Science, Pharmaceutical, Cardiology, Biotechnology, Treatment, Electrophysiology, Private Securities Litigation Reform Act, Biomarker, LinkedIn, Atrial fibrillation, Heart, Left ventricular hypertrophy, Sumathi Best Television Current Reporting Award, ECG, Hypertrophy, Marketing, Risk, Forward-looking statement, HCM, Compliance, Stroke, Research, U.S. Securities and Exchange Commission, Twitter, Goal, LVOT, Facebook, Hypertrophic cardiomyopathy, YouTube, PDUFA, Bristol Myers Squibb, Annual report, Instagram, Blood, Patient, Thrombosis, Security (finance), Silviculture, Liquor, Pharmaceutical industry, Medical device, Diagnosis, MAVACAMTEN, BRISTOL MYERS SQUIBB, MAVACAMTEN, BRISTOL MYERS SQUIBB

Mavacamten has been shown to reduce cardiac muscle contractility by inhibiting excessive myosin-actin cross-bridge formation that results in hypercontractility, left ventricular hypertrophy and reduced compliance.

Key Points: 
  • Mavacamten has been shown to reduce cardiac muscle contractility by inhibiting excessive myosin-actin cross-bridge formation that results in hypercontractility, left ventricular hypertrophy and reduced compliance.
  • Based on data from the EXPLORER-HCM study, the company has a PDUFA date in the U.S. of April 28, 2022.
  • Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook and Instagram .

Bristol Myers Squibb Presents Interim Results from Long-Term Study Reinforcing Maintenance of Response and Safety Profile of Zeposia (ozanimod) in Patients with Moderately to Severely Active Ulcerative Colitis

Retrieved on: 
Thursday, February 17, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Other Health, True North, Ulcerative Colitis, Zeposia (ozanimod), Bristol Myers Squibb, TRUE NORTH, ULCERATIVE COLITIS, ZEPOSIA (OZANIMOD), BRISTOL MYERS SQUIBB

Bristol Myers Squibb (NYSE: BMY) today announced interim results from the True North open-label extension study evaluating the long-term efficacy and safety profile of Zeposia (ozanimod) in patients with moderately to severely active ulcerative colitis (UC).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced interim results from the True North open-label extension study evaluating the long-term efficacy and safety profile of Zeposia (ozanimod) in patients with moderately to severely active ulcerative colitis (UC).
  • Visit this page on BMS.com for more information on Bristol Myers Squibbs scientific approach and resources on gastrointestinal immune-mediated diseases.
  • In the maintenance phase, the overall safety profile was consistent with the known safety profile for Zeposia and patients with moderate to severe UC.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook and Instagram .

Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies

Retrieved on: 
Monday, January 10, 2022
Oncology, Health, Stem Cells, Research, Science, Pharmaceutical, Biotechnology, IPSC, Acute myeloid leukemia, Cancer, B cell, LinkedIn, Sumathi Best Television Current Reporting Award, Security (finance), Goal, Lymphatic system, BMY, Multiple myeloma, Ink, Bristol Myers Squibb, Patient, Marketing, NASDAQ, Adult, U.S. Securities and Exchange Commission, Maintenance, Forward-looking statement, Instagram, Annual report, Science, Program, Probability, Survival, AML, Multimedia, Research, Therapy, Private Securities Litigation Reform Act, NYSE, Diagnosis, Glossary, Risk, YouTube, COVID-19, NK, Life, Twitter, Hematology, Intellectual property, Strathcona County, Genetic engineering, Pharmaceutical industry, Facebook, Century, M.A, Bristol Myers Squibb, Century Therapeutics, BRISTOL MYERS SQUIBB, CENTURY THERAPEUTICS

Bristol Myers Squibb has the option to add two additional programs which can be nominated subject to certain conditions agreed with Century in the agreement.

Key Points: 
  • Bristol Myers Squibb has the option to add two additional programs which can be nominated subject to certain conditions agreed with Century in the agreement.
  • The collaboration with Century Therapeutics is an important part of our investment strategy in next-generation cell therapies for hematologic and solid tumors, said Rupert Vessey , M.A., B.M., B.Ch., F.R.C.P., D.Phil., Executive Vice President & President, Research & Early Development, Bristol Myers Squibb.
  • Centurys iPSC-based gamma delta T and NK cell platforms show promise and are complementary to Bristol Myers Squibbs existing cell therapy technologies.
  • Thereafter, Bristol Myers Squibb will be responsible for clinical development and commercialization activities subject to Centurys co-promotion rights on certain programs.

Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401

Retrieved on: 
Tuesday, December 14, 2021
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Forward-looking statement, Instagram, LinkedIn, Adoptive cell transfer, U.S. Securities and Exchange Commission, Melanoma, Research, Cancer, HLA, Cell, TCR, Clinical trial, CTA, Paul Ehrlich Institute, NYSE, Private Securities Litigation Reform Act, PEI, Celgene, Annual report, NASDAQ, Risk, SEC, Head, Neoplasm, Goal, Patient, Security (finance), Terminology, Sumathi Best Television Current Reporting Award, Development, Bristol Myers Squibb, Multimedia, Program, Cell therapy, YouTube, Twitter, Hart–Scott–Rodino Antitrust Improvements Act, BMY, Sarcoma, Senior, Pharmaceutical industry, Vaccine, Facebook, IMA401, TCER®, Bristol Myers Squibb, Immatics, IMA401, TCER®, BRISTOL MYERS SQUIBB, IMMATICS

In November 2021, Immatics filed a Clinical Trial Application (CTA)1 with Paul-Ehrlich-Institute (PEI), the German federal regulatory authority, for the development of IMA401.

Key Points: 
  • In November 2021, Immatics filed a Clinical Trial Application (CTA)1 with Paul-Ehrlich-Institute (PEI), the German federal regulatory authority, for the development of IMA401.
  • We are delighted to extend our existing collaboration with Bristol Myers Squibb to the IMA401 program and view this as an important validation of the therapeutic potential of our TCER approach.
  • Bristol Myers Squibbs global clinical development and commercialization capabilities in oncology make them the ideal partner for the further development of IMA401.
  • We are pleased to expand our collaboration with Immatics to now include IMA401, said Teri Foy, Senior Vice President, Research and Early Development, Immuno-Oncology and Cell Therapy at Bristol Myers Squibb.

U.S. Food and Drug Administration Approves Orencia® (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD)...

Retrieved on: 
Wednesday, December 15, 2021
FDA, Health, Stem Cells, Clinical Trials, Pharmaceutical, Biotechnology, GVHD-1 (ABA2), GVHD-2, Acute Graft Versus Host Disease and Impact on a Diverse Patient Population, ORENCIA, Bristol Myers Squibb, GVHD-1 (ABA2), GVHD-2, ACUTE GRAFT VERSUS HOST DISEASE AND IMPACT ON A DIVERSE PATIENT POPULATION, ORENCIA, BRISTOL MYERS SQUIBB

Prophylaxis for Acute Graft versus Host Disease: ORENCIA is indicated for the prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age or older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor.

Key Points: 
  • Prophylaxis for Acute Graft versus Host Disease: ORENCIA is indicated for the prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age or older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor.
  • Hypersensitivity: There were 2 cases (
  • Clinically relevant adverse reactions in
  • Primary Clinical Study Report for Study IM101311: Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis.

Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency

Retrieved on: 
Monday, November 29, 2021
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, FDA, Clinical Trials, Deucravacitinib, the Phase 3 POETYK PSO-1 and POETYK PSO-2 Studies, Psoriasis, Bristol Myers Squibb, DEUCRAVACITINIB, THE PHASE 3 POETYK PSO-1 AND POETYK PSO-2 STUDIES, PSORIASIS, BRISTOL MYERS SQUIBB

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis.
  • These latest regulatory milestones are in addition to the NDA acceptance by Japan's Ministry of Health, Labour and Welfare for deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis, pustular psoriasis and erythrodermic psoriasis.
  • Deucravacitinib demonstrated significant and clinically meaningful improvements in skin clearance, symptom burden and quality of life measures compared to placebo and Otezla.
  • Deucravacitinib was well-tolerated with a low rate of discontinuation due to adverse events, with no clinically meaningful lab abnormalities.

Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis

Retrieved on: 
Tuesday, November 23, 2021
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Marketing, Communications, Other Science, Research, Science, Clinical Trials, Royal commission, Patient, Fibrosis, S1P1, BMY, NYSE, Week, Bristol Myers Squibb, Immunology, Physician, UC, True north, Ulcerative colitis, Adult, European Commission, S1P5, Pharmaceutical industry, True North, Ulcerative Colitis, Zeposia (ozanimod), Bristol Myers Squibb, TRUE NORTH, ULCERATIVE COLITIS, ZEPOSIA (OZANIMOD), BRISTOL MYERS SQUIBB

The most common adverse reactions leading to discontinuation were related to liver enzyme elevations (1.1%) in the MS clinical studies.

Key Points: 
  • The most common adverse reactions leading to discontinuation were related to liver enzyme elevations (1.1%) in the MS clinical studies.
  • Bristol Myers Squibb thanks the patients and investigators involved in the True North clinical trial.
  • Bristol Myers Squibb is continuing to evaluate Zeposia in an open-label extension trial, which is ongoing and designed to assess the longer-term profile of Zeposia for the treatment of moderately to severely active UC.
  • The company is also investigating Zeposia for the treatment of moderately to severely active Crohns disease in the ongoing Phase 3 YELLOWSTONE clinical trial program.

Bristol Myers Squibb Awards “Golden Tickets” to Promising Biotechs for Residencies at LabCentral, Biolabs@NYULangone and MBC BioLabs

Retrieved on: 
Thursday, November 18, 2021
Health, Other Science, Clinical Trials, Pharmaceutical, Science, Biotechnology, This Year’s Winning Companies, Bristol Myers Squibb, LabCentral (Cambridge, MA), BioLabs@NYULangone (New York, NY), MBC BioLabs (San Francisco, CA), THIS YEAR’S WINNING COMPANIES, BRISTOL MYERS SQUIBB, LABCENTRAL (CAMBRIDGE, MA), BIOLABS@NYULANGONE (NEW YORK, NY), MBC BIOLABS (SAN FRANCISCO, CA)

Bristol Myers Squibb Company (NYSE:BMY) today announced five innovative biotech startups as winners of the companys 2021 Golden Ticket Contests.

Key Points: 
  • Bristol Myers Squibb Company (NYSE:BMY) today announced five innovative biotech startups as winners of the companys 2021 Golden Ticket Contests.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook and Instagram .
  • In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company.
  • MBC BioLabs has partnerships with leading pharmaceutical and life-science companies as well as a built-in venture capital firm, Mission BioCapital.

Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses

Retrieved on: 
Monday, November 15, 2021
Cardiology, Biotechnology, Other Health, Health, General Health, Pharmaceutical, Other Science, Research, Fitness & Nutrition, Science, Clinical Trials, Safety, TKR, Private Securities Litigation Reform Act, Therapy, Thrombosis, Clinical trial, Leadership, SSP, Security (finance), Sumathi Best Television Current Reporting Award, Bristol Myers Squibb, Risk, Anticoagulant, Goal, Instagram, Research, Facebook, Forward-looking statement, Annual report, Leg, YouTube, Twitter, Sodium, Incidence, U.S. Securities and Exchange Commission, VTE, Xia, LinkedIn, Janssen Pharmaceuticals, Pulmonary embolism, Death, Janssen, Juno Therapeutics, Marketing, Patient, Bleeding, Head, Birth control, Pharmaceutical industry, AXIOMATIC-TKR, Milvexian*, the Bristol Myers Squibb/Janssen Collaboration, Bristol Myers Squibb, AXIOMATIC-TKR, MILVEXIAN*, THE BRISTOL MYERS SQUIBB/JANSSEN COLLABORATION, BRISTOL MYERS SQUIBB

Across a 16-fold range of doses, milvexian demonstrated a low risk of major plus CRNM bleeding, with no major bleeds and no dose-response on this composite outcome.

Key Points: 
  • Across a 16-fold range of doses, milvexian demonstrated a low risk of major plus CRNM bleeding, with no major bleeds and no dose-response on this composite outcome.
  • The clear dose efficacy response without increased bleeding provides additional evidence to support our belief in the promise of milvexian.
  • The TKR study is the first of two studies to read out from the Phase 2 milvexian program.
  • Milvexian is a potential first-in-class oral factor XIa (FXIa) inhibitor (anti-thrombotic) for the prevention and treatment of major thrombotic conditions.

Bristol Myers Squibb Data at ACR Convergence 2021 Illustrate Scientific Advances for Immune-Mediated Rheumatic Diseases

Retrieved on: 
Wednesday, November 3, 2021
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Other Science, Research, Fitness & Nutrition, Science, Clinical Trials, Psoriatic Arthritis, Rheumatoid Arthritis, Lupus, Deucravacitinib, ORENCIA, Bristol Myers Squibb, PSORIATIC ARTHRITIS, RHEUMATOID ARTHRITIS, LUPUS, DEUCRAVACITINIB, ORENCIA, BRISTOL MYERS SQUIBB

These data reinforce Bristol Myers Squibbs commitment to developing new treatments for rheumatic diseases.

Key Points: 
  • These data reinforce Bristol Myers Squibbs commitment to developing new treatments for rheumatic diseases.
  • Bristol Myers Squibb-sponsored abstracts that will be presented at the ACR Convergence 2021 can be found below.
  • Visit this page on BMS.com for more information on Bristol Myers Squibbs scientific approach and resources on rheumatic diseases.
  • In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company.